

**Consent to the Distribution of New Medicines**

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

**Schedule**

<i>Product:</i>	<b>FluQuadri</b>
<i>Active Ingredients:</i>	Influenza virus A/California/7/2009 (H1N1) - like strain 15mcg Influenza virus A/Victoria/361/2011 (H3N2) - like strain 15mcg Influenza virus B/Brisbane/60/2008 - like strain 15mcg Influenza virus B/Massachusetts/2/2012 - like strain 15mcg
<i>Dosage Form:</i>	Suspension for injection
<i>New Zealand Sponsor:</i>	sanofi-aventis new zealand limited
<i>Manufacturer:</i>	Sanofi Pasteur Inc, Pennsylvania, United States of America
<i>Product:</i>	<b>FluQuadri Junior</b>
<i>Active Ingredients:</i>	Influenza virus A/California/7/2009 (H1N1) - like strain 7.5mcg Influenza virus A/Victoria/361/2011 (H3N2) - like strain 7.5mcg Influenza virus B/Brisbane/60/2008 - like strain 7.5mcg Influenza virus B/Massachusetts/2/2012 - like strain 7.5mcg
<i>Dosage Form:</i>	Suspension for injection
<i>New Zealand Sponsor:</i>	sanofi-aventis new zealand limited
<i>Manufacturer:</i>	Sanofi Pasteur Inc, Pennsylvania, United States of America
<i>Product:</i>	<b>Levoclear</b>
<i>Active Ingredient:</i>	Levocetirizine hydrochloride 5mg
<i>Dosage Form:</i>	Film coated tablet
<i>New Zealand Sponsor:</i>	AFT Pharmaceuticals Limited
<i>Manufacturer:</i>	Zaklad Farmaceutyczny Adamed Pharma S.A., Ksawerow, Poland
<i>Product:</i>	<b>Xeomin</b>
<i>Active Ingredient/s:</i>	Botulinum toxin type A 50LD50 Units
<i>Dosage Form:</i>	Powder for injection
<i>New Zealand Sponsor:</i>	New Zealand Medical & Scientific Limited
<i>Manufacturers:</i>	Merz Pharma GmbH & Co KGaA, Dessau-Rosslau, Germany IDT Biologika GmbH, Dessau-Rosslau, Germany
<i>Product:</i>	<b>Xeomin</b>
<i>Active Ingredient:</i>	Botulinum toxin type A 100LD50 Units
<i>Dosage Form:</i>	Powder for injection
<i>New Zealand Sponsor:</i>	New Zealand Medical & Scientific Limited
<i>Manufacturers:</i>	Merz Pharma GmbH & Co KGaA, Dessau-Rosslau, Germany IDT Biologika GmbH, Dessau-Rosslau, Germany
<i>Product:</i>	<b>Zaltrap</b>
<i>Active Ingredient:</i>	Aflibercept 25mg/mL (100mg/4mL)
<i>Dosage Form:</i>	Concentrate for infusion
<i>New Zealand Sponsor:</i>	sanofi-aventis new zealand limited
<i>Manufacturer:</i>	Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany
<i>Product:</i>	<b>Zaltrap</b>
<i>Active Ingredient:</i>	Aflibercept 25mg/mL (200mg/8mL)
<i>Dosage Form:</i>	Concentrate for infusion
<i>New Zealand Sponsor:</i>	sanofi-aventis new zealand limited
<i>Manufacturer:</i>	Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany

Dated this 12th day of December 2014.

CHRIS JAMES, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).